Lonsurf Gains Metastatic Gastric Cancer Indication

The approval was based on data from the phase 3 TAGS trial (N=507) which evaluated Lonsurf plus best supportive care (BSC) vs placebo plus BSC in patients with advanced gastric cancer.

from Latest articles from Cancer Therapy Advisor Gastrointestinal Cancers https://ift.tt/2XstUQD